Pharmaceutical Industry Payments to Medical Oncologists in the Netherlands: Trends and Patterns Provided by an Open-Access Transparency Data Set

• Published in: JCO oncology practice Vol. 20; no. 6; p. 843
• Main Authors: Schnog, J B, Samson, M J, Gersenbluth, I, Duits, A J
• Format: Journal Article
• Language: English
• Published: United States 01.06.2024
• Subjects: Conflict of Interest - economics; Cross-Sectional Studies; Drug Industry - economics; Humans; Netherlands; Oncologists - economics; Retrospective Studies; Netherlands
• ISSN: 2688-1535
• DOI: 10.1200/OP.23.00533

Health care expenditure related to oncologic treatments is skyrocketing although many treatments offer marginal, if any, clinical benefit. Financial conflicts of interest (fCOI) resulting from pharmaceutical industry (pharma) payments to physicians is increasingly recognized as a predictive factor for regulatory board approval and guideline incorporation of low-value treatments. We sought to study the extent to which pharma payments to medical oncologists occur in the Netherlands, the amount of money involved, and whether these occur more frequently and are higher for key opinion leaders (KOLs). In our cross-sectional retrospective database study, we used several Dutch open-access databases and extracted data registered between 2019 and 2021. A cumulative amount of €899,863 was paid to 48.8% of the 408 registered medical oncologists. Over time, there was a marked decline in both the proportion of medical oncologists receiving payments (from 40.4% in 2019 to 19.1% in 2021) and the mean annual value of payments (from €2,962 in 2019 to €2,188 in 2021) with the latter mainly resulting from a decline in hospitality-related transactions. KOLs were more likely to receive industry payments and received a higher median payment value. Our findings should contribute to the increasing awareness in the Netherlands of the potential effects of fCOI.